Sutro Biopharma Financials - Benzinga

Sutro Biopharma Inc

STRONASDAQ

Trade with Public

Trade with Public

$25.38

1.235.09%

At close: Aug 7, 5:00 PM EST

$25.38

N/A

After Hours: Aug 7, 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Sutro Biopharma Financials

Sutro Biopharma (STRO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Sutro Biopharma Q1 EPS $(2.94) Beats $(3.77) Estimate, Sales $14.523M Beat $8.079M Estimate

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.94) per share which beat the analyst consensus estimate of $(3.77) by 22.02 percent. This is a 67.69 percent increase over losses of $(9.10) per share from

Benzinga Newsdesk

PRO
Sutro Biopharma Q4 EPS $(5.29) Misses $(4.35) Estimate, Sales $11.647M Beat $8.341M Estimate

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(5.29) per share which missed the analyst consensus estimate of $(4.35) by 21.58 percent. This is a 40.56 percent increase over losses of $(8.90) per share from

Benzinga Newsdesk

PRO
Sutro Biopharma Q3 EPS $(0.67) Misses $(0.41) Estimate, Sales $9.693M Beat $9.132M Estimate

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.41) by 65.02 percent. This is a 13.56 percent decrease over losses of $(0.59) per share from

Benzinga Newsdesk

PRO
Sutro Biopharma To Continue To Reorganize Restructuring And Related Costs For Deprioritzation Of Luvelta Program; Expected To Recognize Portion In 2025

Benzinga Newsdesk

PRO
Sutro Biopharma Q2 EPS $(0.14) Beats $(0.45) Estimate, Sales $63.74M Beat $14.35M Estimate

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.45) by 68.68 percent. This is a 76.27 percent increase over losses of $(0.59) per share from

Benzinga Newsdesk

PRO
Sutro Biopharma Q1 EPS $(0.91) Misses $(0.71) Estimate, Sales $17.40M Beat $11.61M Estimate

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.71) by 28.17 percent. This is a 4.21 percent increase over losses of $(0.95) per share from

Benzinga Newsdesk